With the tremendous advances in cardiac pacing during the past four decades, cardiac pacemaker implantation is now a common clinical procedure. In recent years, the indications for permanent pacemakers have expanded. This increase in reasons for pacing and shift in mode of pacing have been caused by the evolution of pacemaker therapy from a life-saving measure (mortality), to one aimed at improving healthrelated quality of life (HRQoL). Until now the efficacy of pacing therapy has predominantly been measured using bobjectiveQ criteria. However, in recent years the importance of HRQoL as an outcome measure has increasingly been recognized as patients prefer quality over quantity of life.In this review we describe the development and testing of Aquarel, a new developed HRQoL questionnaire for pacemaker patients, composed of a generic core module with disease specific add-ons. Current and future research to improve the Aquarel questionnaire is also described. D 2005 Elsevier Ireland Ltd. All rights reserved.Keywords: Cardiac pacing; Quality of life; Aquarel In the Netherlands there is an increased implantation rate of cardiac pacemakers in patients of all ages over the past decade (Fig. 1). This increase in the number of implanted pacemaker-units and leads combined with a rising population age contribute to an increase in hospitalisation, care and follow-up. Until now the efficacy of pacing therapy has predominantly been measured using clinical outcomes such as improvement of prognosis, relief of symptoms, complications, technical failures and recalls. However, to evaluate the full spectrum of outcome of pacemaker therapy patient reported outcomes as well as clinical outcomes should be measured. In recent years the importance of health-related quality of life (HRQoL) as an outcome measure has increasingly been recognized [1,2]. This has particular relevance in cardiac pacing because the goal of therapy for most patients with chronic disease is improvement in function, not cure [3]. These measures should be incorporated as one of the primary measures of outcome in the evaluation of new therapies in chronic diseases including cardiac pacing. Doing so, clinicians, patients, policymakers, health care providers and HRQoL researchers gain experience with these measures.To measure HRQoL, appropriate instruments should be used and a large number of questionnaires has been developed in the past two decades. However, in the field of cardiac pacing until recently several instruments were used to measure HRQoL that were not properly validated and applied [4][5][6][7][8][9][10][11][12][13][14][15][16][17]. Consequently these HRQoL data should be interpreted cautiously. HRQoL is typically measured either in a generic or a specific way. Generic means that an instrument gives information on several dimensions and is useful for a variety of illnesses, diseases and different (patient-) populations, allowing for comparison between these (patient-) populations. Disease specific questionnaires focus on dimensions most relevant ...